Overview

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2 expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma (HCC). This study is being done to: - Test the safety and tolerability of TKM-080301 in subjects with advanced hepatocellular carcinoma - Find the highest dose of TKM-080301 that can be given without causing side effects, called the maximum tolerated dose (MTD). - Provide a preliminary assessment of anti-tumor activity of TKM-080301
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arbutus Biopharma Corporation